MyLife Technologies (Leiden, the Netherlands) is a clinical-stage company offering ceramic Micro-needle Array Patches, the 3^rd generation MAPs. CeraMAPs™ deliver vaccines in the upper layers of the skin, which contain the immune cells responsible for high immunization efficiency in vaccination. We target vaccine projects to protect against infectious diseases and for cancer therapies.

CeraMAPs enable three major breakthroughs in vaccine distribution and delivery compared to standard injections in muscle or sub-cutaneous fat:

·        5x-20x less vaccine actives required, and no/less need for adjuvants

·        Dry product form possible, stored and distributed at ambient temperatures.

·        “Just a patch on the arm”: no pain, no blood, no needle anxiety; applied effortless within 30 seconds.

CeraMAPs™ feature 3 essential advantages over 2^nd generation micro-needles:

1.      CeraMAPs™ ceramic material is chemically inert for both vaccine-actives and skin tissue, offering maximum freedom of formulation for vaccine developers.

2.      We offer the highest load & release capacity with high precision tip-loading for many different types of vaccines.

3.      Thanks to the semi-conductor processing technology we apply, manufacturing CeraMAPs™ is highly cost competitive and very scalable.

CeraMAPs™ can offer significant cost-of-delivery savings and improved uptake for vaccination campaigns, and for “Rapid Response & Outbreak Control”.  

Status:

·        Phase 2A Clinical Trial in preparation with commercial Seasonal Influenza for Q4-2024

·        Therapeutic vaccine development against HPV-induced cervical cancer

·        Pre-clinical mRNA/DNA polymeric nano-particle delivery

·        Scale-up development for a Pilot Plant to supply clinical trials and early commercial volumes

·        Pre-clinical P-o-C studies on Influenza/ Diphtheria/ Tetanus

·        7 granted base-patents in US-EU-CHN-JPN, new patents pending

Partnering:

We collaborate in vaccine delivery projects offering feasibility studies, co- development, licenses, and supply of patches.